Alveolus Bio

Alveolus Bio is an early-stage biotech developing first-in-class inhaled live biotherapeutics for chronic respiratory diseases. The company's core innovation is the resMIT platform, designed for targeted pulmonary delivery of bacteria to modulate the lung microbiome and treat underlying disease mechanisms like fibroblast dysfunction and inflammation. With a strong, interdisciplinary team and a preclinical pipeline targeting high-need indications such as IPF and COPD, Alveolus Bio is positioned to pursue a novel therapeutic approach in a field dominated by small molecules and biologics. The company is privately held, pre-revenue, and actively seeking investment and partnerships to advance its programs.

proprietary resMIT (Respiratory Microbiome Inspired Therapeutics) platform for the discovery, formulation, and targeted pulmonary delivery of live biotherapeutic products (LBPs) to address fibroblast dysfunction and neutrophilic inflammation.

The field of inhaled live biotherapeutics for lung disease is nascent, with few direct competitors. However, Alveolus Bio competes indirectly with large pharma companies developing small molecules, biologics, and gene therapies for IPF and COPD, and may face future competition from other microbiome-focused entrants.